Biogen Inc. (BIIB) was upgraded to a "buy" by TheStreet's Quant Ratings service on Wednesday. This biotech name has made a chart that could be challenging to many traders and investors. Let's drill down and see if an easier approach to the long side can be found.
More from Stocks
Let's review three high-yield business development companies.
Here are six ways to handle the two biggest risks.
The hurt Fed Chair Jerome Powell has been talking about so much lately is no longer an abstract concept on Wall Street. But with the horrible action comes opportunities.
Traders are are trying to find bottoms on an ugly day in the markets